Class of Stock [Axis] Common Stock, $0.001 par value per share 8.625% Senior Notes due 2026 11.875% Senior Notes due 2027 Product and Service [Axis] Product Sales Net [Member] Other Revenues [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Harrow Health Inc Stockholders Equity [Member] Noncontrolling Interest [Member] Legal Entity [Axis] Eton Pharmaceuticals, Inc. [Member] Investment, Name [Axis] Melt Pharmaceuticals, Inc. [Member] Investment Type [Axis] Preferred Stock [Member] Surface Ophthalmics Inc [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Finite-Lived Intangible Assets by Major Class [Axis] New Drug Applications [Member] Antidilutive Securities [Axis] Stock Options, Unvested RSUs And Unvested PSUs [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Loan [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Debt Instrument [Axis] 2016 Notes [Member] 2027 Notes [Member] Oaktree Loan [Member] Commissions [Member] Transfer Of Acquired Product Sales Profits [Member] Business Acquisition [Axis] VEVYE [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Santen Products Acquisition [Member] Scenario [Axis] One Time Payment [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Asset Purchase Agreement [Member] RPC Agreement [Member] Sintetica Agreement [Member] Upfront Payment [Member] Income Statement Location [Axis] Research and Development Expense [Member] Management Services Agreement [Member] Series B Preferred Stock [Member] Melt Loan Agreement [Member] Related Party, Type [Axis] Third Party Investor [Member] Series B1 Preferred Stock [Member] Related Party Transaction [Axis] Capitalized Internal Use Software [Member] Third Party Software License [Member] Capitalized Software Development Costs [Member] Patents [Member] Licenses [Member] Trademarks [Member] Customer Relationships [Member] Trade Names [Member] Non-Competition Clause [Member] State Pharmacy Licenses [Member] Acquired New Drug Applications [Member] Financing Agreement [Member] Forecast [Member] Oaktree Fund Administration LLC [Member] Long-Term Debt, Type [Axis] Senior Secured Term Loan [Member] Variable Rate [Axis] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Oaktree Credit Agreement Amendment [Member] Senior Notes Due 2027 [Member] 8.625% Senior Notes Due 2026 [Member] Title of Individual [Axis] Investor [Member] Loan and Security Agreement [Member] BR Loan [Member] Long-Lived Tangible Asset [Axis] Office and Laboratory Space [Member] Geographical [Axis] Carlsbad [Member] Ledgewood [Member] Lease Amendment [Member] Nashville [Member] Nashville 1 [Member] Common Stock Offering [Member] Performance Stock Units [Member] Director [Member] Share-Based Payment Arrangement, Option [Member] Mark LBaum [Member] Andrew R Boll [Member] John Saharek [Member] Warrant [Member] Consultant [Member] Consultant One [Member] Consultant Two [Member] Employees [Member] Plan Name [Axis] 2017 Incentive Stock and Awards Plan [Member] Stock Option Plan [Member] Employees and Consultant [Member] Employees and Directors [Member] Performance Stock Units PSU [Member] Unvested PSU [Member] Directors [Member] Unvested RSU [Member] Unvested RSUs And PSU [Member] Stock Option Plan [Member] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Range Five [Member] Range Six [Member] Range Seven [Member] Range Eight [Member] Range Nine [Member] Range Ten [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Share-Based Payment Arrangement, Tranche Three [Member] Share Based Compensation Award Tranche Four [Member] Selling, General and Administrative Expenses [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] State and Local Jurisdiction [Member] Reasearch and Development [Member] Internal Revenue Service (IRS) [Member] Sales and Marketing Agreements [Member] Asset Purchase, License and Related Agreements [Member] Klarity License Agreement [Member] Richard L. Lindstrom, M.D [Member] Initial Payment [Member] Second Payment [Member] Final Payment [Member] Injectable Asset Purchase Agreement [Member] Lindstrom Agreement [Member] Presbyopia Asset Purchase Agreement [Member] Dexycu Agreement [Member] Two Product Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Product Concentration Risk [Member] Customer [Axis] Single Customer [Member] Accounts Receivable [Member] Customer Concentration Risk [Member] Three Suppliers [Member] Supplier Concentration Risk [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Investment in Eton Pharmaceuticals Accounts receivable, net Inventories Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Capitalized software costs, net Deferred financing costs Operating lease right-of-use assets, net Intangible assets, net Goodwill TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable and accrued expenses Accrued rebates and copay assistance Accrued payroll and related liabilities Deferred revenue and customer deposits Current portion of operating lease obligations Total current liabilities Operating lease obligations, net of current portion Accrued expenses, net of current portion Notes payable, net of unamortized debt discount and issuance costs TOTAL LIABILITIES Commitments and contingencies STOCKHOLDERS’ EQUITY Common stock, $0.001 par value, 50,000,000 shares authorized, 35,168,260 and 29,901,530 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated deficit TOTAL HARROW, INC. STOCKHOLDERS’ EQUITY Noncontrolling interests TOTAL STOCKHOLDERS’ EQUITY TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Revenues: Total revenues Cost of sales Gross profit Operating expenses: Selling, general and administrative Research and development Impairment of intangible assets Total operating expenses Income from operations Other (expense) income: Interest expense, net Equity in losses of unconsolidated entities Investment gain (loss) from Eton Pharmaceuticals Loss on extinguishment of debt Gain on sale of non-ophthalmology assets Other (expense) income, net Total other expense, net Loss before income tax provision Income tax provision Net loss attributable to Harrow, Inc. Basic net loss per share of common stock Diluted net loss per share of common stock Weighted average number of shares of common stock outstanding, basic Weighted average number of shares of common stock outstanding, diluted Balance Balance, shares Exercise of consultant stock-based options Exercise of consultant stock based options, shares Exercise of employee stock-based options Exercise of employee stock-based options, shares Exercise of warrants Exercise of warrants, shares Vesting of RSUs and PSUs Vesting of RSUs and PSUs, shares Shares withheld related to net share settlement of equity awards Shares withheld related to net share settlement of equity awards, shares Issuance of common shares from public offering, net of offering costs Issuance of common shares from public offering, net of offering costs, shares Stock-based compensation expense Net loss Public offering, net of offering costs Public offering, net of offering costs, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization of property, plant and equipment and software development costs Amortization of intangible assets Amortization of operating lease right-of-use assets Provision for credit losses Amortization of debt issuance costs and debt discount Investment (gain) loss from investment in Eton Equity in losses of unconsolidated entities Loss on disposal of equipment Impairment of intangible assets Loss on extinguishment of debt Stock-based compensation Gain on sale of non-ophthalmology assets Changes in assets and liabilities: Accounts receivable Inventories Prepaid expenses and other current assets Accounts payable, accrued expenses, accrued rebates and copay assistance Accrued payroll and related liabilities Deferred revenue and customer deposits NET CASH PROVIDED BY OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of non-ophthalmology assets Investment in patent and trademark assets Proceeds from sale of property, plant and equipment Purchase of product NDAs, marketing authorizations and patents Purchases of property, plant and equipment NET CASH USED IN INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from 11.875% notes payable, net of costs Proceeds from Oaktree Loan, net of costs Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options Proceeds from exercise of stock options Proceeds from B Riley senior secured note, net of costs Repayment of B. Riley senior secured note Proceeds from public offering of common stock, net of offering costs Payments on finance lease obligations NET CASH PROVIDED BY FINANCING ACTIVITIES NET CHANGE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, beginning of year CASH AND CASH EQUIVALENTS, end of year SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for income taxes Cash paid for interest SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Reclassification of deferred financing costs Accrual of exit fee related to Oaktree Loan Insurance premium financed Purchase of intangible asset included in accounts payable and accrued expenses Purchase of property, plant and equipment included in accounts payable and accrued expenses Right-of-use assets obtained in exchange for new operating lease obligations Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue from Contract with Customer [Abstract] REVENUES Business Combination and Asset Acquisition [Abstract] RECENT PRODUCT ACQUISITIONS, LICENSES AND DIVESTITURES Investments, Debt and Equity Securities [Abstract] INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS – RELATED PARTY TRANSACTIONS Investment In Surface Ophthalmics Inc. And Agreements - Related Party Transactions INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS Inventory Disclosure [Abstract] INVENTORIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER CURRENT ASSETS Property, Plant and Equipment [Abstract] PROPERTY, PLANT AND EQUIPMENT Capitalized Software Costs CAPITALIZED SOFTWARE COSTS Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS AND GOODWILL Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Debt Disclosure [Abstract] DEBT Leases LEASES Equity [Abstract] STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Income Tax Disclosure [Abstract] INCOME TAXES Retirement Benefits [Abstract] EMPLOYEE SAVINGS PLAN Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Segment Reporting [Abstract] SEGMENTS AND CONCENTRATIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Use of Estimates Risks, Uncertainties and Liquidity Credit Losses Business Combinations and Asset Acquisitions Noncontrolling Interests Revenue Recognition and Deferred Revenue Cost of Sales Research and Development Debt Issuance Costs and Debt Discount Intellectual Property Income Taxes Cash and Cash Equivalents Concentrations of Credit Risk Investment in Eton Pharmaceuticals, Inc. Accounts Receivable Inventories Investment in Melt Pharmaceuticals, Inc. – Related Party Investment in Surface Ophthalmics, Inc. – Related Party Property, Plant and Equipment Capitalized Software Costs Goodwill and Intangible Assets Impairment of Other Long-Lived Assets Leases Fair Value Measurements Stock-Based Compensation Basic and Diluted Net Loss per Common Share Recently Adopted Accounting Pronouncements Reclassifications SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS SCHEDULE OF INVESTMENT SCHEDULE OF ESTIMATED FAIR VALUE SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE SCHEDULE OF DISAGGREGATED REVENUE SCHEDULE OF NET GAIN ON SALE OF ASSETS SCHEDULE OF CONDENSED INCOME STATEMENT SCHEDULE OF CONDENSED BALANCE SHEET SCHEDULE OF INVENTORIES SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT SCHEDULE OF CAPITALIZED SOFTWARE COSTS SCHEDULE OF INTANGIBLE ASSETS SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES SCHEDULE OF LONG TERM DEBT SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES SCHEDULE OF STOCK OPTION PLAN ACTIVITY SCHEDULE OF FAIR VALUE ASSUMPTIONS SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE SCHEDULE OF PERFORMANCE STOCK UNITS SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS SCHEDULE OF PROVISION FOR INCOME TAXES SCHEDULE OF INCOME TAX PROVISION SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES SCHEDULE OF UNRECOGNIZED TAX BENEFITS Beginning balance Change in expected credit losses Write-offs, net of recoveries Ending balance Schedule of Investments [Table] Schedule of Investments [Line Items] Cost Basis Share of Equity Method Losses Net carrying value Paid in Kind Interest In Substance Capital Contributions Platform Operator, Crypto-Asset [Table] Platform Operator, Crypto-Asset [Line Items] Carrying value Fair value Numerator – net loss attributable to Harrow, Inc. Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Consolidation basis description Accounts receivable, net of allowances for credit losses Noncontrolling interest, description Deferred financing costs Unrecognized tax benefits Cash, FDIC Insured Amount Investments related to change in fair market value of its investment Investment owned balance shares Ownership percentage Shares price Investment owned at fair value Accounts receivable, net Accounts receivable, contractual adjustments Accounts Receivable, after Allowance for Credit Loss Reduction in investment Investment interest rate Due from related parties Property, plant and equipment, useful life Estimated useful life Impairment charge Stock options, unvested RSUs, and unvested PSUs Vested RSU Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Contract with customer liability current Gross consideration Closing and transaction costs Net proceeds Customer relations intangible asset Gain on sale of non-ophthalmology assets Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business acquired percentage Royalty payments Acquisition of assets and capitalized the initial payments Costs associated transaction Costs incurred Milestone payment Term milestone payment Purchase price acquisition Purchase price acquisition Proceeds from related party Milestones receivable based on agreed revenues Cash Receivable amount Payments received from accounts receivable Amount payable Inventory, gross Accrued expense Reduction milestone payment Revenues, net Loss from operations Current assets Non-current assets Total assets Total liabilities Total preferred stock and stockholders’ equity (deficit) Total liabilities and stockholders’ equity Administrative fees expense Reimbursable expenses Repaid of related parties Gross proceeds from third party investors Sold shares Face amount Debt instrument interest rate stated percentage Reimbursable expenses Received shares Fair value Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Investment owned shares Reduction in common stock investment Raw materials Work in progress Finished goods Total inventories Prepaid insurance Prepaid computer software related expenses Other prepaid expenses Receivable due from Melt Prepaid PDUFA fees Deferred Oaktree commitment fee (see Note 13) Deposits and other current assets Total prepaid expenses and other current assets Computer hardware Furniture and equipment Lab and pharmacy equipment Leasehold improvements Property, plant and equipment, gross Accumulated depreciation and amortization Property, plant and equipment, net Gain loss on disposition of assets Depreciation and amortization expenses Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Total gross capitalized software for internal-use Accumulated amortization Capitalized internal-use software in process Total capitalized software costs net Amortization expenses Intangible assets, Useful life Intangible assets, Cost Intangible assets, Accumulated amortization Intangible assets, Impairment Intangible assets, Net Carrying value Useful life, description 2024 2025 2026 2027 2028 Thereafter Intangible assets  Impairment charge Carrying value of goodwill Accounts payable Accrued insurance premium Accrued IHEEZO milestone payments (see Note 4) Accrued RPC transition payments (see Note 4) Accrued exit fee for note payable (see Note 13) Accrued litigation settlements Accrued interest (see Note 13) Total accounts payable and accrued expenses Less: current portion Non-current total accrued expenses Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Debt instrument interest rate, during period Accrued monthly payments Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Notes payable gross  Less: Unamortized debt discount and issuance costs Notes payable net  2024 2025 2026 2027 Total minimum payments Less: amount representing interest payments Notes payable, gross Less: unamortized discount, net of premium Notes payable, net of unamortized discount Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Debt principal amount Debt instrument increase (decrease) for period net Proceeds from issuance of debt Interest rate Debt instrument maturity date Effective interest rate Original debt discount Loss on extinguishment of debt Accrued expenses Warrants to purchase shares Interest expense Amortization of deferred commitment fees Interest rate Shares issued price per share Deducting underwriting discounts and commissions and expenses Redemption description Interest expense debt Debt instrument unamortized premium Schedule Of Future Lease Payment Under Operating Leases 2024 2025 2026 2027 2028 Thereafter Total minimum lease payments Less: amount representing imputed interest payments Total operating lease liabilities Less: current portion, operating lease liabilities Lease term Area of land Lease expiration date, description Area of land Weighted average discount rate percent Lease term Operating lease payments Operating lease expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of shares, outstanding, beginning balance Weighted average exercise price, outstanding, beginning balance Number of shares, options granted Weighted average exercise price, options granted Number of shares, options exercised Weighted average exercise price, options exercised Number of shares, options cancelled/forfeited Weighted average exercise price, options cancelled/forfeited Number of shares, outstanding, ending balance Weighted average exercise price, outstanding, ending balance Weighted average. remaining contractual life, options outstanding Aggregate intrinsic value, options outstanding Number of shares, options exercisable Weighted average exercise price, options exercisable Weighted average. remaining contractual life, options exercisable Aggregate intrinsic value, options exercisable Number of shares, options vested and expected to vest Weighted average exercise price, options vested and expected to vest Weighted average. remaining contractual life, options vested and expected to vest Aggregate intrinsic value, options exercisable Weighted-average fair value of options granted Expected terms (in years) Expected volatility, minimum Expected volatility, maximum Risk-free interest rate, minimum Risk-free interest rate, maximum Dividend yield Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of Exercise Prices, minimum Range of Exercise Prices, maximum Number of Options Outstanding Weighted Average Remaining Contractual Life in Years Weighted Average Exercise Price Number Options Exercisable Weighted Average Exercisable Exercise Price Number of Shares Target Share Price Number of Shares, PSUs unvested, outstanding, beginning balance Weighted average grant date fair value, beginning balance Number of Shares, PSUs granted Weighted average grant date fair value, PSUs granted Number of Shares, PSUs vested Weighted average grant date fair value, PSUs vested Number of Shares, PSUs cancelled/forfeited Weighted average grant date fair value, PSUs cancelled/forfeited Number of Shares, PSUs unvested, outstanding, ending balance Weighted average grant date fair value, ending balance Number of Shares, RSUs granted Weighted average grant date fair value, RSUs granted Number of Shares, RSUs vested Weighted average grant date fair value, RSUs vested Number of Shares, RSUs cancelled/forfeited Weighted average grant date fair value, RSUs cancelled/forfeited Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Total Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Preferred stock, shares authorized Preferred stock, par or stated value per share Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, par or stated value per share Offering price per share Number of shares sold Net proceeds from common stock Other expenses Number of shares outstanding TSR percentage Shares withheld for tax withholding obligation, shares Payroll tax obligations, value Number of common stock shares issued Shares vested during period Proceeds from stock option exercise Exercise of option, shares Exercise price, minimum Exercise price, maximum Cashless exercise of options, shares Exercise price per share Additional shares withheld for tax withholding obligation Number of shares granted Warrants exercise price Common stock withheld on cashless exercise Common stock withheld for payroll tax withholdings, shares Common stock withheld for payroll tax withholdings, value Number of securities called by warrants Warrants exercise price Number of shares authorized Common shares available for future issuances Closing price of common stock price per share Intrinsic value Vesting term description Forfeiture factor rate Unrecognized compensation expense Weighted-average period years Share price Shares vested, fair market value Volatality rate Risk free intrest rate Current: Federal State Total current Deferred: Federal State Total deferred Income tax provision U.S. federal statutory tax rate State tax benefit, net Rate change Employee stock-based compensation Excess employee remuneration Melt loan settlement Other Uncertain tax positions Research and development tax credit Provision-to-return true-ups Other true-ups Change in valuation allowance Effective income tax rate NOL Depreciation and amortization Other Research and development credits Deferred stock compensation Basis difference in Eton Basis difference in Melt investments Federal benefit of state ASC740-10 reserves Limitation Under 163(j) Section 174 capitalized expenses ASC 842 lease liability ASC 842 ROU asset Total deferred tax assets, net Valuation allowance Net deferred tax assets Balance at January 1, 2023 Additions for tax positions related to current year Additions for tax positions related to prior years Balance at December 31, 2023 Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Valuation allowance Net operating loss carryforwards State operating loss carryforwards State net operating loss expiration date Federal net operating loss carryforward description Research and development tax credits Federal and state research and development tax credits expiration date Federal credit State credits Unrecognized Tax Benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate Income Tax Examination, Penalties and Interest Accrued Percentage of salary deposits in tax deferred investment account Percentage of contributions made by the company Contributions by the company Loss Contingencies [Table] Loss Contingencies [Line Items] Description for commission payments Commission payments percentage Commission expenses Accounts payable and other accrued liabilities Royalty expense Royalty payment description Net sales Milestone payment in cash Additional milestone payment in cash Initial milestone payment Milestone payment due Commission revenues Schedule of Revenue by Major Customers, by Reporting Segments [Table] Revenue, Major Customer [Line Items] Concentration risk percentage Subsequent Event [Table] Subsequent Event [Line Items] Number of shares issued Proceeds from issuance of common stock Options to purchase common shares 11.875% Senior Notes due 2027 [Member] 8.625% Senior Notes due 2026 [Member] Common Stock, $0.001 par value per share Accrued rebates and copay assistance. Equity in losses of unconsolidated entities. Gain on sale of non-ophthalmology assets. Total Harrow Health Inc Stockholders Equity [Member] Issuance of common shares from public offering, net of offering costs. Exercise of warrants. Exercise of warrants, shares Loss on disposal of equipment. Gain on sale of non-ophthalmology assets. Purchase of product NDAs, marketing authorizations and patents. Proceeds from 11.875% notes payable, net of costs. Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options. Reclassification of deferred financing costs. Accrual of exit fee related to Oaktree Loan. Insurance premium financed. Purchase of intangible asset included in accounts payable and accrued expenses. Purchase of property, plant and equipment included in accounts payable and accrued expenses. Product Sales Net [Member] Proceeds from sale of non-ophthalmology assets. Consolidation basis, description. Risks Uncertainties And Liquidity [Policy Text Block] Noncontrolling Interest [Policy Text Block] Eton Pharmaceuticals, Inc. [Member] Accounts receivable, contractual adjustments. Investment One [Policy Text Block] Melt Pharmaceuticals, Inc. [Member] Reduction in investment. Loan [Member] Investment paid in kind interest. Investment Two [Policy Text Block] Surface Ophthalmics Inc [Member] New Drug Applications [Member] 2016 Notes [Member] 2027 Notes [Member] Stock Options, Unvested RSUs And Unvested PSUs [Member] Transfer Of Acquired Product Sales Profits [Member] VEVYE [Member] Santen Products Acquisition [Member] Milestone payment. Term milestone payment. One Time Payment [Member] Asset Purchase Agreement [Member] Milestones receivable based on agreed revenues. RPC Agreement [Member] Closing and transaction costs. Sintetica Agreement [Member] Upfront Payment [Member] Reduction milestone payment. Management Services Agreement [Member] Melt Loan Agreement [Member] Third Party Investor [Member] Reimbursable expenses. Series B1 Preferred Stock [Member] Investments And Agreements Related Party Transactions [Text Block] Reduction in common stock investment. Receivable due from related party. Deferred commitment fee. Computer hardware gross. Capitalized Software Costs [Text Block] Capitalized Software Development Costs [Table Text Block] Capitalized computer software internal use in process. Capitalized Software Development Costs [Member] Accrued transitional fees current and non current. Accrued exit fee for note payable current and non current. Accrued ligitation settlements current and noncurrent. Financing Agreement [Member] Accrued monthly payments. Oaktree Fund Administration LLC [Member] Senior Secured Term Loan [Member] Licenses [Member] Non-Competition Clause [Member] State Pharmacy Licenses [Member] Finite lived intangible assets impairment. Oaktree Credit Agreement Amendment [Member] Senior Notes Due 2027 [Member] Deferred financing costs. 8.625% Senior Notes Due 2026 [Member] Loan and Security Agreement [Member] BR Loan [Member] Office and Laboratory Space [Member] Carlsbad [Member] Lease expiration date description. Ledgewood [Member] Additional area of land. Lease Amendment [Member] Nashville [Member] Nashville 1 [Member] Common Stock Offering [Member] Performance Stock Units [Member] Percentage of stock holders return. Mark LBaum [Member] Cashless exercise of options shares. Addtional shares paid for tax withholding for share based compensation. Andrew R Boll [Member] John Saharek [Member] Cashless exercise of options price per shares Common stock withheld on cashless exercise Consultant [Member] Consultant One [Member] Consultant Two [Member] Employees [Member] 2017 Incentive Stock and Awards Plan [Member] Stock Option Plan [Member] Closing price of common stock price per share. Stock Option Plan [Member] Employees and Consultant [Member] Forfeiture factor rate. Employees and Directors [Member] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Range Five [Member] Range Six [Member] Range Seven [Member] Range Eight [Member] Range Nine [Member] Range Ten [Member] Performance Stock Units PSU [Member] Share Based Compensation Award Tranche Four [Member] Schedule Of Share Based Compensation Performance Stock Units Award Activity [Table Text Block] Unvested PSU [Member] Directors [Member] Unvested RSU [Member] Unvested RSUs And PSU [Member] Effective income tax rate reconciliation excess employee remuneration. Effective income tax rate reconciliation uncertain tax position Effective income tax rate reconciliation provision to return true ups Deferred Tax Asset Tax Credit carry Forwards Depreciation And Amortization. Deferred tax assets research and development. Basis Difference in Eton. Income tax basis difference in investments Deferred tax assets tax deferred capital expense limitations. Deferred tax assets tax deferred lease liability expense limitations. Deferred tax assets tax deferred right of use assets expense limitations. Deferred tax assets federal benefit of state reserves Deferred tax assets limitations State net operating loss expiration date. Federal net operating loss carryforward description Federal and state research and development tax credits expiration date. Reasearch and Development [Member] Federal tax credit from deferred tax assets with a corresponding reduction of valuation allowance. State tax credit from deferred tax assets with a corresponding reduction of valuation allowance. Percentage of salary deposits in tax deferred investment account. Description for commission payments. Sales and Marketing Agreements [Member] Commission payments, percentage. Asset Purchase, License and Related Agreements [Member] Royalty payment description. Klarity License Agreement [Member] Richard L. Lindstrom, M.D [Member] Initial Payment [Member] Second Payment [Member] Net sales revenue. Final Payment [Member] Milestone payment in cash. Additional milestone payment in cash. Injectable Asset Purchase Agreement [Member] Initial milestone payment. Lindstrom Agreement [Member] Presbyopia Asset Purchase Agreement [Member] Milestone payments on payables. Commission revenues Dexycu Agreement [Member] Two Product Concentration Risk [Member] Single Customer [Member] Three Suppliers [Member] Stock issued during period value issuance of common shares from public offering net of offering costs shares. Deferred tax assets tax deferred capitalized expenses limitations Stock Option Plan [Member] [Default Label] Assets, Current Liabilities, Current Equity, Including Portion Attributable to Noncontrolling Interest Cost of Goods and Services Sold Gross Profit Operating Expenses Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Shares, Outstanding Gain on sale of non-ophthalmology assets [Default Label] Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Employee Related Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options Repayments of Senior Debt Finance Lease, Principal Payments Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Inventory, Policy [Policy Text Block] Research, Development, and Computer Software, Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Accounts Receivable, Allowance for Credit Loss, Writeoff Equity Method Investment, Aggregate Cost Investment Company, Committed Capital DeferredFinancingCosts AccountsReceivables Gain (Loss) on Disposition of Assets for Financial Service Operations Business Combination, Price of Acquisition, Expected ReimbursableExpenses Debt Instrument, Fair Value Disclosure Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Capitalized Computer Software, Accumulated Amortization Finite-Lived Intangible Assets, Net Accounts Payable and Accrued Liabilities Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Long-Term Debt Interest Payable, Current Extinguishment of Debt, Amount Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Additional square footage Operating Lease, Weighted Average Remaining Lease Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Class of Warrant or Right, Exercise Price of Warrants or Rights Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Effective Income Tax Rate Reconciliation, Percent Basis Difference in Eton DeferredTaxAssetsTaxDeferredRightOfUseAssetsExpenseLimitations Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net